Literature DB >> 28597077

Is Rosai-Dorfman disease a reactve process? Detection of a MAP2K1 L115V mutation in a case of Rosai-Dorfman disease.

Matthias S Matter1, Michel Bihl1, Darius Juskevicius1, Alexandar Tzankov2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28597077     DOI： 10.1007/s00428-017-2173-4

Source DB:  PubMed          Journal:  Virchows Arch        ISSN： 0945-6317            Impact factor:   4.064


× No keyword cloud information.
  15 in total

1.  High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.

Authors:  Julien Haroche; Frédéric Charlotte; Laurent Arnaud; Andreas von Deimling; Zofia Hélias-Rodzewicz; Baptiste Hervier; Fleur Cohen-Aubart; David Launay; Annette Lesot; Karima Mokhtari; Danielle Canioni; Louise Galmiche; Christian Rose; Marc Schmalzing; Sandra Croockewit; Marianne Kambouchner; Marie-Christine Copin; Sylvie Fraitag; Felix Sahm; Nicole Brousse; Zahir Amoura; Jean Donadieu; Jean-François Emile
Journal:  Blood       Date:  2012-08-09       Impact factor: 22.113

2.  Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies.

Authors:  Chengliang Dong; Peng Wei; Xueqiu Jian; Richard Gibbs; Eric Boerwinkle; Kai Wang; Xiaoming Liu
Journal:  Hum Mol Genet       Date:  2014-12-30       Impact factor: 6.150

Review 3.  Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.

Authors:  Jean-François Emile; Oussama Abla; Sylvie Fraitag; Annacarin Horne; Julien Haroche; Jean Donadieu; Luis Requena-Caballero; Michael B Jordan; Omar Abdel-Wahab; Carl E Allen; Frédéric Charlotte; Eli L Diamond; R Maarten Egeler; Alain Fischer; Juana Gil Herrera; Jan-Inge Henter; Filip Janku; Miriam Merad; Jennifer Picarsic; Carlos Rodriguez-Galindo; Barret J Rollins; Abdellatif Tazi; Robert Vassallo; Lawrence M Weiss
Journal:  Blood       Date:  2016-03-10       Impact factor: 22.113

4.  Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity.

Authors:  J Rosai; R F Dorfman
Journal:  Arch Pathol       Date:  1969-01

5.  Development of disseminated histiocytic sarcoma in a patient with autoimmune lymphoproliferative syndrome and associated Rosai-Dorfman disease.

Authors:  Girish Venkataraman; Kenneth L McClain; Stefania Pittaluga; V Koneti Rao; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2010-04       Impact factor: 6.394

6.  MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis.

Authors:  David S Nelson; Astrid van Halteren; Willemijn T Quispel; Cor van den Bos; Judith V M G Bovée; Bhumi Patel; Gayane Badalian-Very; Paul van Hummelen; Matthew Ducar; Ling Lin; Laura E MacConaill; R Maarten Egeler; Barrett J Rollins
Journal:  Genes Chromosomes Cancer       Date:  2015-03-31       Impact factor: 5.006

Review 7.  MAP kinase signalling pathways in cancer.

Authors:  A S Dhillon; S Hagan; O Rath; W Kolch
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

8.  Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.

Authors:  Eli L Diamond; Benjamin H Durham; Julien Haroche; Zhan Yao; Jing Ma; Sameer A Parikh; Zhaoming Wang; John Choi; Eunhee Kim; Fleur Cohen-Aubart; Stanley Chun-Wei Lee; Yijun Gao; Jean-Baptiste Micol; Patrick Campbell; Michael P Walsh; Brooke Sylvester; Igor Dolgalev; Olga Aminova; Adriana Heguy; Paul Zappile; Joy Nakitandwe; Chezi Ganzel; James D Dalton; David W Ellison; Juvianee Estrada-Veras; Mario Lacouture; William A Gahl; Philip J Stephens; Vincent A Miller; Jeffrey S Ross; Siraj M Ali; Samuel R Briggs; Omotayo Fasan; Jared Block; Sebastien Héritier; Jean Donadieu; David B Solit; David M Hyman; José Baselga; Filip Janku; Barry S Taylor; Christopher Y Park; Zahir Amoura; Ahmet Dogan; Jean-Francois Emile; Neal Rosen; Tanja A Gruber; Omar Abdel-Wahab
Journal:  Cancer Discov       Date:  2015-11-13       Impact factor: 39.397

9.  Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.

Authors:  Rikhia Chakraborty; Oliver A Hampton; Xiaoyun Shen; Stephen J Simko; Albert Shih; Harshal Abhyankar; Karen Phaik Har Lim; Kyle R Covington; Lisa Trevino; Ninad Dewal; Donna M Muzny; Harshavardhan Doddapaneni; Jianhong Hu; Linghua Wang; Philip J Lupo; M John Hicks; Diana L Bonilla; Karen C Dwyer; Marie-Luise Berres; Poulikos I Poulikakos; Miriam Merad; Kenneth L McClain; David A Wheeler; Carl E Allen; D Williams Parsons
Journal:  Blood       Date:  2014-09-08       Impact factor: 22.113

10.  Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.

Authors:  Zoran Gatalica; Nurija Bilalovic; Juan P Palazzo; Ryan P Bender; Jeffrey Swensen; Sherri Z Millis; Semir Vranic; Daniel Von Hoff; Robert J Arceci
Journal:  Oncotarget       Date:  2015-08-14
View more
  14 in total

1.  BRAF-V600E-mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitor.

Authors:  Rosemarie Mastropolo; Allison Close; Steven W Allen; Kenneth L McClain; Scott Maurer; Jennifer Picarsic
Journal:  Blood Adv       Date:  2019-06-25

Review 2.  Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.

Authors:  Matthias Papo; Fleur Cohen-Aubart; Ludovic Trefond; Adeline Bauvois; Zahir Amoura; Jean-François Emile; Julien Haroche
Journal:  Curr Oncol Rep       Date:  2019-05-21       Impact factor: 5.075

Review 3.  [Updates to the WHO classification of bone tumours].

Authors:  G Jundt
Journal:  Pathologe       Date:  2018-03       Impact factor: 1.011

Review 4.  Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease.

Authors:  Oussama Abla; Eric Jacobsen; Jennifer Picarsic; Zdenka Krenova; Ronald Jaffe; Jean-Francois Emile; Benjamin H Durham; Jorge Braier; Frédéric Charlotte; Jean Donadieu; Fleur Cohen-Aubart; Carlos Rodriguez-Galindo; Carl Allen; James A Whitlock; Sheila Weitzman; Kenneth L McClain; Julien Haroche; Eli L Diamond
Journal:  Blood       Date:  2018-05-02       Impact factor: 22.113

5.  BRAF V600E mutation detected in a case of Rosai-Dorfman disease.

Authors:  Giancarlo Fatobene; Julien Haroche; Zofia Hélias-Rodzwicz; Frédéric Charlotte; Valérie Taly; Aliana Meneses Ferreira; André Néder Ramires Abdo; Vanderson Rocha; Jean-François Emile
Journal:  Haematologica       Date:  2018-05-10       Impact factor: 9.941

6.  Rosai-Dorfman Disease-Utility of 18F-FDG PET/CT for Initial Evaluation and Follow-up.

Authors:  Sonia Mahajan; Reiko Nakajima; Mariko Yabe; Ahmet Dogan; Gary A Ulaner; Joachim Yahalom; Ariela Noy; Eli L Diamond; Heiko Schöder
Journal:  Clin Nucl Med       Date:  2020-06       Impact factor: 7.794

7.  Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease.

Authors:  Gaurav Goyal; Aishwarya Ravindran; Jason R Young; Mithun V Shah; N Nora Bennani; Mrinal M Patnaik; Grzegorz S Nowakowski; Gita Thanarajasingam; Thomas M Habermann; Robert Vassallo; Taimur Sher; Sameer A Parikh; Karen L Rech; Ronald S Go
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

8.  NRAS Mutations May Be Involved in the Pathogenesis of Cutaneous Rosai Dorfman Disease: A Pilot Study.

Authors:  Kuan-Jou Wu; Shu-Hao Li; Jia-Bin Liao; Chien-Chun Chiou; Chieh-Shan Wu; Chien-Chin Chen
Journal:  Biology (Basel)       Date:  2021-05-02

9.  [Rosai-Dorfman disease: a clinicopathologic analysis and whole exome sequencing in 23 cases].

Authors:  W J Fu; J Du; J Lu; L Z Wang; J M Yang; M X He; X X Hu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-08-14

10.  Histiocytic cell neoplasms involving the bone marrow: summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016.

Authors:  Alexandar Tzankov; Markus Kremer; Roos Leguit; Attilio Orazi; Jon van der Walt; Umberto Gianelli; Konnie M Hebeda
Journal:  Ann Hematol       Date:  2018-08-06       Impact factor: 3.673
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.